Since to date, the gliptins and GLP1-RAs are important drugs for the treatment of T2DM, it could be of interest to find and target “new” specific miRNAs substrates modulated by GLP1, which affect the pathogenesis of metabolic diseases. The gene discussed is GCG; the disease is metabolic disease.